|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
Human influenza hemagglutinin (HA) is a surface glycoprotein required for the infectivity of the human virus. The HA tag is derived from the HA-molecule corresponding to amino acids 98-106 has been extensively used as a general epitope tag in expression vectors. Many recombinant proteins have been engineered to express the HA tag, which does not appear to interfere with the bioactivity or the biodistribution of the recombinant protein. This tag facilitates the detection, isolation, and purification of the proteins.
The actual HA tag is as follows: 5' TAC CCA TAC GAT GTT CCA GAT TAC GCT 3' or 5' TAT CCA TAT GAT GTT CCA GAT TAT GCT 3' The amino acid sequence is: YPYDVPDYA.
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-GFPSpark tag||HG10015-ACG|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-Flag tag||HG10015-CF|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-His tag||HG10015-CH|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-Myc tag||HG10015-CM|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, C-HA tag||HG10015-CY|
|Human GM-CSF/CSF2 Gene ORF cDNA clone in cloning vector||HG10015-G|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-Flag tag||HG10015-NF|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-His tag||HG10015-NH|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-Myc tag||HG10015-NM|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid, N-HA tag||HG10015-NY|
|Human GM-CSF/CSF2 Gene ORF cDNA clone expression plasmid||HG10015-UT|
|Learn more about expression Vectors|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 (cellular) immune responses in cognate T cells. The active form of the protein is found extracellularly as a homodimer, and the encoding gene is localized to a related gene cluster at chromosome region 5q31 which is known to be associated with 5q-syndrome and acute myelogenous leukemia. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients. GM-CSF deficiency in pregnancy adversely impacts fetal and placental development, as well as progeny viability and growth after birth, highlighting this cytokine as a central maternal determinant of pregnancy outcome with clinical relevance in human fertility.